Clinical Dilemmas in Non–Alcoholic Fatty Liver Disease
Samenvatting
Clinical Dilemmas in Non–Alcoholic Fatty Liver Disease offers hepatologists practical, up–to–date and expert guidance on the most topical dilemmas, difficulties and areas of controversy/difficulty surrounding this ever–increasing area of liver disease they face in daily practice.
Roger Williams and Simon Taylor–Robinson, two of Europe s leading hepatologists, have recruited leading figures from across the world to assist them, resulting in a truly international approach. Each chapter covers a specific area of difficulty, containing clear learning points and providing evidence–based expert guidance on the latest hot topics in clinical management such as:
Is NAFLD different in absence of Metabolic Syndrome?
Are the pros outweighed by the cons of obtaining a liver biopsy?
Is progression to cirrhosis more likely in children with NAFLD?
What are the dangers as well as the true benefits of bariatric surgery?
How is it best to use antifibrotic agents in clinical practice?
Clinical Dilemmas in Non–Alcoholic Fatty Liver Disease provides the answers to the questions and challenges that clinicians face every day in this area. It is essential reading for hepatologists of all levels and researchers in hepatology, as well as all those involved in the care of patients with NAFLD, including gastroenterologists, pathologists and specialist hepatology nurses.
Specificaties
Inhoudsopgave
<p>Preface ix</p>
<p>Part I: Nature of the condition</p>
<p>1 Non–alcoholic fatty liver disease: Hype or harm? 3<br /> Stephen H. Caldwell and Curtis K. Argo</p>
<p>2 NAFLD: A worldwide problem 8<br /> Joanna K. Dowman, Geoffrey C. Farrell, and Philip Newsome</p>
<p>3 Is insulin resistance the principal cause of NAFLD? 15<br /> Ian F. Godsland, Sanjeev Mehta, Shareen Forbes, Fabian Meienberg, Michael Yee, Simon D. Taylor–Robinson, and Desmond G. Johnston</p>
<p>4 Paediatric NAFLD: A distinct disease with the propensity for progressive fibrosis 29<br /> Emer Fitzpatrick and Anil Dhawan</p>
<p>5 Non–alcoholic fatty liver disease (NAFLD) as cause of cryptogenic cirrhosis 36<br /> Jay H. Lefkowitch</p>
<p>6 Is NAFLD different in absence of metabolic syndrome? 44<br /> Yusuf Yilmaz</p>
<p>7 Occurrence of noncirrhotic HCC in NAFLD 50<br /> Dawn M. Torres and Stephen A. Harrison</p>
<p>Part II: Factors in Disease Progression</p>
<p>8 Fibrosis progression: Putative mechanisms and molecular pathways 61<br /> Wing–Kin Syn and Anna Mae Diehl</p>
<p>9 When is it NAFLD and when is it ALD?: Can the histologic evaluation of a liver biopsy guide the clinical evaluation? 72<br /> Elizabeth M. Brunt and David E. Kleiner</p>
<p>10 Of men and microbes: Role of the intestinal microbiome in non–alcoholic fatty liver disease 82<br /> Muhammad Bilal Siddiqui, Mohammed Shadab Siddiqui, and Arun J. Sanyal</p>
<p>11 Can genetic influence in non–alcoholic fatty liver disease be ignored? 91<br /> Yang–Lin Liu, Christopher P. Day, and Quentin M. Anstee</p>
<p>12 Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events? 103<br /> Soo Lim</p>
<p>Part III: Diagnosis and Scoring</p>
<p>13 How to best diagnose NAFLD/NASH? 113<br /> Vlad Ratziu</p>
<p>14 The clinical utility of noninvasive blood tests and elastography 124<br /> Emmanuel A. Tsochatzis and Massimo Pinzani</p>
<p>15 Are the guidelines AASLD, IASL, EASL, and BSG of help in the management of patients with NAFLD? 131<br /> Cristina Margini and Jean–François Dufour</p>
<p>16 Imaging methods for screening of hepatic steatosis 138<br /> Hero K. Hussain</p>
<p>17 Are the advantages of obtaining a liver biopsy outweighed by the disadvantages? 152<br /> Jeremy F. L. Cobbold and Simon D. Taylor–Robinson</p>
<p>18 Screening for NAFLD in high–risk populations 161<br /> Nader Lessan</p>
<p>Part IV: Value of treatment measures</p>
<p>19 Defining the role of metabolic physician 173<br /> Nicholas Finer</p>
<p>20 Should physicians be prescribing or patients self–medicating with orlistat, vitamin E, vitamin D, insulin sensitizers, pentoxifylline, or coffee? 182<br /> Haripriya Maddur and Brent A. Neuschwander–Tetri</p>
<p>21 Effects of treatment of NAFLD on the metabolic syndrome 189<br /> Hannele Yki–Järvinen</p>
<p>22 What are the dangers as well as the true benefits of bariatric surgery? 196<br /> Andrew Jenkinson</p>
<p>23 Liver transplantation: What can it offer? 203<br /> Roger Williams</p>
<p>Part V: What does the future hold?</p>
<p>24 Molecular antagonists, leptin or other hormones in supplementing environmental factors? 211<br /> Jonathan M. Hazlehurst and Jeremy W. Tomlinson</p>
<p>25 What is the role of antifibrotic therapies in the current and future management of NAFLD? 218<br /> Natasha McDonald and Jonathan Fallowfield</p>
<p>26 Developmental programming of non–alcoholic fatty liver disease 226<br /> Jiawei Li, Paul Cordero, and Jude A. Oben</p>
<p>Index 232</p>